AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20688033 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 626
Study 20688033 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 626
Study 20688033 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DES and BMS
Number of subjects: 626
Study 17506001 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem 0.5 g x 3 for 5-7 days
Number of subjects: 73
Study 17506001 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 73
Study 15682068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow (BM) Transplantation
Number of subjects: 72
Study 15682068 — intervention group
Group type: COMPARATOR
Intervention: Peripheral Blood Stem Cell (PBSC) Transplantation
Number of subjects: 72
Study 12131234 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living intervention
Number of subjects: 0
Study 12131234 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial activity intervention
Number of subjects: 0
Study 12131234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of activities of daily living and psychosocial activity intervention
Number of subjects: 0
Study 12131234 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study 12131234 — intervention group
Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 0
Study 11721446 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol plus Ginkgo biloba (EGb)
Number of subjects: 54
Study 11721446 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol plus placebo
Number of subjects: 54
Study 11721446 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 54
Study 7595267 — intervention group
Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 0
Study 7595267 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2301243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 30
Study 2301243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7436639 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-operated hypertension group
Number of subjects: 52
Study 7436639 — intervention group
Group type: COMPARATOR
Intervention: Nurse-operated hypertension clinic (control)
Number of subjects: 52
Study 31845141 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-completed approach
Number of subjects: 3756
Study 31845141 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach (intention-to-treat)
Number of subjects: 3756
Study 31845141 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 3756
Study 31845141 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Hartmann's procedure and primary anastomosis
Number of subjects: 3756
Study 31845141 — intervention group
Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 3756
Study 30808847 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Hemodiafiltration (pre-dilution mode)
Number of subjects: 22
Study 30808847 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Hemodiafiltration (post-dilution mode)
Number of subjects: 22
Study 30808847 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 22
Study 28580579 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg FI
Number of subjects: 340
Study 28580579 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab 300 mg RAN
Number of subjects: 340
Study 24909549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m(2) on RT days 1, 22, and 43 (Arm A)
Number of subjects: 69
Study 24909549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (20 mg/m(2)/day) and 5-fluorouracil (5-FU; 1000 mg/m(2)/day) continuous 96-hour infusions on RT weeks 1 and 4 (Arm B)
Number of subjects: 69
Study 23845018 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 45
Study 23845018 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone extended release (ER)
Number of subjects: 45
Study 23845018 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone ER placebo
Number of subjects: 45
Study 21514033 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Improvement (PGI-I)
Number of subjects: 299
Study 18495387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulus method for assessing mammographic density
Number of subjects: 177
Study 18495387 — intervention group
Group type: COMPARATOR
Intervention: Standard mammogram form (SMF) for assessing mammographic density
Number of subjects: 177
Study 17060764 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LGBP)
Number of subjects: 83
Study 17060764 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic vertical banded gastroplasty (LVBG)
Number of subjects: 83
Study 17060764 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LGBP) and Laparoscopic vertical banded gastroplasty (LVBG)
Number of subjects: 83
Study 12735661 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 125 microg b.i.d.
Number of subjects: 27
Study 12735661 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 50 microg b.i.d.
Number of subjects: 27
Study 12735661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 10652956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential estrogen/progestin (beta estradiol/norethisterone acetate)
Number of subjects: 90
Study 10652956 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous estrogen/progestin (beta estradiol/norethisterone acetate)
Number of subjects: 90
Study 10652956 — intervention group
Group type: COMPARATOR
Intervention: Estrogen alone (beta estradiol)
Number of subjects: 90
Study 10652956 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/progestin-treated women
Number of subjects: 90
Study 10652956 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/progestin groups
Number of subjects: 90
Study 10652956 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with > or = 50% drop in B‐ALP at 6 months
Number of subjects: 90
Study 10652956 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in B‐ALP at 6 months
Number of subjects: 90
Study 9330124 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20
Study 9330124 — intervention group
Group type: COMPARATOR
Intervention: Spirapril
Number of subjects: 20
Study 9330124 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study 1534042 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 18
Study 1534042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 4036269 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine against measles, mumps, and rubella (two doses: first at 18 months, second at 12 years)
Number of subjects: 247
Study 4036269 — intervention group
Group type: COMPARATOR
Intervention: Urban areas
Number of subjects: 247
Study 4036269 — intervention group
Group type: COMPARATOR
Intervention: Rural areas
Number of subjects: 247
Study 29882281 — intervention group
Group type: EXPERIMENTAL
Intervention: UDS video training module
Number of subjects: 20
Study 29882281 — intervention group
Group type: COMPARATOR
Intervention: Standard UDS teaching document
Number of subjects: 20
Study 27311730 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg IV days 1 and 15) and Everolimus (10 mg PO daily)
Number of subjects: 17
Study 24984192 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 16
Study 24984192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22160931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 210
Study 22160931 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 210
Study 20231565 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate 3.0 g/d
Number of subjects: 81
Study 20231565 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate 3.5 g/d
Number of subjects: 81
Study 20231565 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate 4.0 g/d
Number of subjects: 81
Study 20231565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 18385624 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training (15 sessions using force platform biofeedback)
Number of subjects: 41
Study 18385624 — intervention group
Group type: COMPARATOR
Intervention: Conventional stroke inpatient rehabilitation program
Number of subjects: 41
Study 16284466 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate gel
Number of subjects: 180
Study 16284466 — intervention group
Group type: COMPARATOR
Intervention: K-Y Jelly
Number of subjects: 180
Study 12882907 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 0
Study 12882907 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 12882907 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise
Number of subjects: 0
Study 10450427 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 120
Study 10450427 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-users of ITNs)
Number of subjects: 120
Study 9231304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (mean 324 mg daily)
Number of subjects: 40
Study 9231304 — intervention group
Group type: COMPARATOR
Intervention: Typical neuroleptics (mean 465 mg chlorpromazine‐equivalents daily)
Number of subjects: 40
Study 1806186 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD3 monoclonal antibodies
Number of subjects: 0
Study 1806186 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF monoclonal antibodies
Number of subjects: 0
Study 6410547 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1) for 3 months
Number of subjects: 40
Study 6410547 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 40
Study 30773022 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18139
Study 30773022 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18139
Study 27078990 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpi Liqi Yiliu Formula (JLYF) combined with cytokine‐induced killer (CIK) cells treatment
Number of subjects: 60
Study 27078990 — intervention group
Group type: COMPARATOR
Intervention: Cytokine‐induced killer (CIK) cells treatment
Number of subjects: 60
Study 25263143 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave therapy (1 application with 1000 impulses at 0.19 to 0.23 mJ per square millimeter)
Number of subjects: 30
Study 25263143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (deactivated shock-wave applicator and acoustic sham)
Number of subjects: 30
Study 22047909 — intervention group
Group type: EXPERIMENTAL
Intervention: Two portions of farmed salmon weekly (n=47)
Number of subjects: 88
Study 22047909 — intervention group
Group type: COMPARATOR
Intervention: Normal diet low in fish (n=41)
Number of subjects: 88
Study 22047909 — intervention group
Group type: COMPARATOR
Intervention: Both salmon and control groups
Number of subjects: 88
Study 19530746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 160 mg
Number of subjects: 39
Study 19530746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg
Number of subjects: 39
Study 19530746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 39
Study 17697301 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal midazolam (0.2 mg/kg)
Number of subjects: 36
Study 17697301 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide/oxygen (30%/70%)
Number of subjects: 36
Study 15705728 — intervention group
Group type: EXPERIMENTAL
Intervention: Six sessions of sprint interval training (SIT) over 2 weeks with 1-2 days rest between sessions
Number of subjects: 8
Study 15705728 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 8
Study 12119852 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9852446 — intervention group
Group type: EXPERIMENTAL
Intervention: Stents placed above the sphincter of Oddi
Number of subjects: 34
Study 9852446 — intervention group
Group type: COMPARATOR
Intervention: Stents placed across the sphincter of Oddi
Number of subjects: 34
Study 8034814 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation
Number of subjects: 0
Study 8034814 — intervention group
Group type: COMPARATOR
Intervention: Litigation
Number of subjects: 0
Study 8034814 — intervention group
Group type: COMPARATOR
Intervention: Mediation and Litigation
Number of subjects: 0
Study 3058407 — intervention group
Group type: EXPERIMENTAL
Intervention: Subhepatic drain
Number of subjects: 200
Study 3058407 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tube
Number of subjects: 200
Study 3058407 — intervention group
Group type: COMPARATOR
Intervention: Postoperative iv-infusions
Number of subjects: 200
Study 26976433 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander education program
Number of subjects: 969
Study 26976433 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional awareness education program
Number of subjects: 969
Study 26976433 — intervention group
Group type: COMPARATOR
Intervention: No education control group
Number of subjects: 969
Study 28752410 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection (serious infections post-stroke)
Number of subjects: 4011
Study 28752410 — intervention group
Group type: COMPARATOR
Intervention: No infection
Number of subjects: 4011
Study 25160009 — intervention group
Group type: EXPERIMENTAL
Intervention: FACETS programme (group-based fatigue management programme)
Number of subjects: 164
Study 25160009 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis-Fatigue Self-Efficacy scale (8-item)
Number of subjects: 164
Study 23832605 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF gene polymorphisms (rs6265, rs12273539, rs10835210)
Number of subjects: 709
Study 23832605 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype rs6265 (A)-rs12273539 (C)-rs10835210 (A)
Number of subjects: 709
Study 21498062 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tramadol 2.0 mg/kg
Number of subjects: 70
Study 21498062 — intervention group
Group type: COMPARATOR
Intervention: Tramadol infiltration at trocar sites 2.0 mg/kg in 20 mL of 0.9% NaCl
Number of subjects: 70
Study 18636958 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg per day
Number of subjects: 30
Study 18636958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir 400 mg and 100 mg twice per day
Number of subjects: 30
Study 18636958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18636958 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Atazanavir, Lopinavir-ritonavir, Placebo)
Number of subjects: 30
Study 17030655 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid treatment (1.7 g of docosahexaenoic acid and 0.6 g of eicosapentaenoic acid daily)
Number of subjects: 204
Study 17030655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 12918865 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow taping technique
Number of subjects: 16
Study 12918865 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 16
Study 11222823 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with rtPA given within six hours of stroke onset
Number of subjects: 0
Study 11222823 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9734743 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g/d)
Number of subjects: 116
Study 9734743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 8283290 — intervention group
Group type: EXPERIMENTAL
Intervention: L. GG yogurt (2 x 150 mL/d, containing 10(11) cfu/L of L. GG)
Number of subjects: 64
Study 8283290 — intervention group
Group type: EXPERIMENTAL
Intervention: L. GG yogurt with rye fiber product (30 g/d, equivalent to 9 g fiber/d)
Number of subjects: 64
Study 8283290 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt and fiber
Number of subjects: 64
Study 8283290 — intervention group
Group type: EXPERIMENTAL
Intervention: L. GG yogurt (with or without fiber)
Number of subjects: 64
Study 2538676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (1000 mg over 24 h) - short-term treatment
Number of subjects: 14
Study 2538676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (600 mg/die for 1 week up to 12 months) - long-term treatment
Number of subjects: 14
Study 31977371 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 10 mg nalbuphine with 18 mL of 100 mg ropivacaine
Number of subjects: 90
Study 31977371 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 20 mg nalbuphine with 18 mL of 100 mg ropivacaine
Number of subjects: 90
Study 31977371 — intervention group
Group type: COMPARATOR
Intervention: 2 mL of normal saline with 18 mL of 100 mg ropivacaine
Number of subjects: 90
Study 31367958 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemic clamp (plasma glucose 3.0 ± 0.2 mmol/l)
Number of subjects: 25
Study 31367958 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemic clamp (plasma glucose 6.0 ± 0.2 mmol/l)
Number of subjects: 25
Study 31367958 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemic clamp
Number of subjects: 25
Study 28152542 — intervention group
Group type: EXPERIMENTAL
Intervention: RMI/RCOG
Number of subjects: 148
Study 28152542 — intervention group
Group type: COMPARATOR
Intervention: SRMP
Number of subjects: 148
Study 26561621 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate intake (median: 238 g/d)
Number of subjects: 222
Study 26561621 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate intake (median: 188 g/d)
Number of subjects: 222
Study 26561621 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal intake of digestible carbohydrates in late pregnancy
Number of subjects: 222
Study 22682526 — intervention group
Group type: EXPERIMENTAL
Intervention: E5 (five exposures to fruit)
Number of subjects: 95
Study 22682526 — intervention group
Group type: EXPERIMENTAL
Intervention: E5+ (five plus exposures to fruit)
Number of subjects: 95
Study 22682526 — intervention group
Group type: COMPARATOR
Intervention: E1 (one exposure to fruit)
Number of subjects: 95
Study 22682526 — intervention group
Group type: EXPERIMENTAL
Intervention: E5 and E5+ (comparison between groups)
Number of subjects: 95
Study 22682526 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure interventions
Number of subjects: 95
Study 21653735 — intervention group
Group type: EXPERIMENTAL
Intervention: GH substitution (9-12 months, placebo controlled)
Number of subjects: 0
Study 21653735 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/IGF1 stimulation in hFOB (osteoblasts)
Number of subjects: 0
Study 21653735 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/IGF1
Number of subjects: 0
Study 21653735 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF1 presence with SFLLRN stimulation
Number of subjects: 0
Study 19361304 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccine
Number of subjects: 304
Study 19361304 — intervention group
Group type: COMPARATOR
Intervention: Virosomal vaccine
Number of subjects: 304
Study 19361304 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccine (among HIV-infected patients)
Number of subjects: 304
Study 19361304 — intervention group
Group type: COMPARATOR
Intervention: Virosomal vaccine (among HIV-infected patients)
Number of subjects: 304
Study 19361304 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccine (among renal transplant patients)
Number of subjects: 304
Study 19361304 — intervention group
Group type: COMPARATOR
Intervention: Virosomal vaccine (among renal transplant patients)
Number of subjects: 304
Study 16625311 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of solifenacin once daily
Number of subjects: 1873
Study 16625311 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of solifenacin once daily
Number of subjects: 1873
Study 16625311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1873
Study 16997737 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg imMP with placebo tablets
Number of subjects: 27
Study 16997737 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection with prednisolone 30 mg daily
Number of subjects: 27
Study 11704123 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized 17beta‐E(2), 2 mg/day orally (cycle days 1 to 28)
Number of subjects: 39
Study 11704123 — intervention group
Group type: COMPARATOR
Intervention: Micronized 17beta‐E(2), administered vaginally (cycle days 1 to 28)
Number of subjects: 39
Study 9191528 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC)
Number of subjects: 27
Study 9191528 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 27
Study 8106156 — intervention group
Group type: EXPERIMENTAL
Intervention: 175 mg/m2 TAXOL administered by 3-h infusion
Number of subjects: 407
Study 8106156 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mg/m2 TAXOL administered by 3-h infusion
Number of subjects: 407
Study 8106156 — intervention group
Group type: EXPERIMENTAL
Intervention: 175 mg/m2 TAXOL administered by 24-h infusion
Number of subjects: 407
Study 8106156 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mg/m2 TAXOL administered by 24-h infusion
Number of subjects: 407
Study 31094248 — intervention group
Group type: EXPERIMENTAL
Intervention: WUV5%
Number of subjects: 19
Study 31094248 — intervention group
Group type: EXPERIMENTAL
Intervention: WUV10%
Number of subjects: 19
Study 31094248 — intervention group
Group type: EXPERIMENTAL
Intervention: WUV15%
Number of subjects: 19
Study 31094248 — intervention group
Group type: COMPARATOR
Intervention: Unloaded condition (control)
Number of subjects: 19